Chemomab is a clinical-stage biotechnology company developing innovative therapeutics targeting fibro-inflammatory diseases with high unmet medical needs.[1] Its lead candidate, nebokitug, is a monoclonal antibody that neutralizes the soluble protein CCL24, which drives fibrosis and inflammation; it has demonstrated a favorable safety profile in clinical and preclinical studies and targets severe conditions like primary sclerosing cholangitis (PSC), systemic sclerosis (SSc), and other life-threatening fibro-inflammatory disorders.[1]
Chemomab serves patients with rare and debilitating diseases lacking effective treatments, solving the core problem of uncontrolled fibrosis and inflammation that leads to organ damage.[1] The company has reported positive Phase 2 results from the SPRING trial in PSC, meeting safety endpoints and showing improvements in disease progression markers, with recent FDA alignment on a single Phase 3 pivotal trial—positioning nebokitug as a potential first approved therapy for PSC without needing biopsies or confirmatory studies.[1] Growth momentum includes ongoing Phase 3 preparations, an open U.S. IND for SSc, and discussions with strategic partners.[1]
Chemomab emerged from research highlighting the pivotal role of CCL24 in fibrosis and inflammation, leading to the development of nebokitug as a targeted monoclonal antibody.[1] While specific founder details are not detailed in available sources, the company's focus crystallized around CCL24's unique mechanism, validated through preclinical studies showing nebokitug's broad potential across fibro-inflammatory diseases.[1]
Early traction came from clinical trials, including the Phase 2 SPRING trial in PSC patients, which delivered positive 15-week and 48-week results—achieving primary safety endpoints and secondary improvements in moderate-to-advanced disease.[1] Pivotal moments include FDA alignment on a streamlined Phase 3 pathway for PSC, derisking the program with data suggesting reduced clinical events like disease progression.[1]
Chemomab rides the wave of precision immunology in biotech, targeting specific cytokines like CCL24 amid rising focus on fibrosis-modifying therapies for rare diseases.[1] Timing is ideal as PSC and SSc lack approved treatments, with market forces like accelerated FDA pathways and orphan drug incentives favoring derisked assets—evidenced by SPRING trial successes and Phase 3 readiness.[1]
The company influences the ecosystem by validating CCL24 as a novel target, potentially inspiring similar antibody platforms and attracting partnerships to scale fibro-inflammatory innovation.[1]
Chemomab is poised for a Phase 3 readout in PSC, with partner deals likely accelerating commercialization of nebokitug as a breakthrough for unmet needs.[1] Trends like AI-driven target discovery and fibrosis-focused M&A will shape its path, evolving its influence from clinical pioneer to multi-disease leader in immunology.[1] This positions Chemomab to transform fibro-inflammatory care, building directly on its CCL24 innovation.
Chemomab has raised $30.0M in total across 2 funding rounds.
Chemomab's investors include Presight Capital, 5eyes Ventures, Founder Collective, Founders Fund, Justin Mateen.
Chemomab has raised $30.0M across 2 funding rounds. Most recently, it raised $20.0M Series C in November 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2019 | $20.0M Series C | Presight Capital | |
| Dec 1, 2017 | $10.0M Series B | 5eyes Ventures, Founder Collective, Founders Fund, Justin Mateen |
